BioCentury
ARTICLE | Financial News

Lysosomal raises $4.8 million in seed financing

May 13, 2014 2:05 AM UTC

Lysosomal Therapeutics Inc. (Cambridge, Mass.) raised $4.8 million in a seed financing led by Atlas Venture. Hatteras Venture Partners; Lilly Ventures; Sanofi-Genzyme BioVentures; Roche Venture Fund; Partners Innovation Fund; Orion Equity Partners; and angel investors also participated. Lysosomal Therapeutics is developing small molecules that can cross the blood-brain barrier (BBB) to increase the activity of glucocerebrosidase (GBA; GCase) in the lysosome and to reduce the risk of Parkinson's disease. The company's lead program targets Gaucher-related neurodegeneration, PD and other synucleinopathies. Gaucher's disease is caused by GCase deficiency. The company said it is about three years away from clinical testing. ...